BioSig Technologies, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioSig Technologies, Inc. (the "Company") on July 21, 2014, covering events occurring on July 14 and July 15, 2014. The Company is a Delaware corporation headquartered in Los Angeles, California, focused on developing medical technology, specifically the PURE EP technology platform.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes and executive compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size to nine members.
- New Appointments: Patrick Gallagher and Gregory Cash were appointed as directors effective July 15, 2014.
- Executive Leadership: Gregory Cash was appointed as President and Chief Executive Officer.
Management Commentary, Compensation, and Risks
Employment Agreement Terms:
- Term: Three years, expiring July 15, 2017.
- Base Salary: $275,000 annually. Automatically increases to $325,000 upon a "Qualified Financing" (equity raise of at least $3.5 million) or if no such financing occurs within six months (unless failure is within Mr. Cash's control).
- Bonus: Eligible for an annual bonus of at least 50% of base salary plus one-time payments, contingent on performance criteria and financing milestones.
- Severance: Termination without cause or for good reason entitles Mr. Cash to one year of base salary and one year of benefits, plus accrued bonuses.
Stock Option Grant:
- Grant Size: 1,265,769 shares of common stock.
- Exercise Price: $2.21 per share (fair market value on grant date).
- Vesting Schedule:
- 542,473 shares vest quarterly over 11 installments.
- 180,824 shares vest immediately upon a Qualified Financing.
- 180,824 shares vest upon listing on a U.S. national securities exchange.
- 180,824 shares vest upon FDA 510(k) clearance of the PURE technology.
- 180,824 shares vest upon achieving and maintaining a $150 million market capitalization for 90 days.
Risks and Contingencies: The Company's ability to meet the vesting milestones for the CEO's stock options is contingent on significant future events, including securing $3.5 million in financing, achieving regulatory clearance, and reaching a specific market capitalization. Failure to secure financing within six months triggers a salary increase but may indicate liquidity challenges.
Investor Verification Checklist
- Verify the Company's current cash position and runway to determine the likelihood of a "Qualified Financing" within six months.
- Confirm the status of the PURE EP technology platform and its timeline for FDA 510(k) clearance.
- Review the full text of the Employment Agreement (Exhibit 10.1) and Incentive Stock Option Agreement (Exhibit 10.2) for specific performance criteria definitions.
- Assess the dilution impact of the 1,265,769 shares granted to the CEO relative to the current outstanding share count.
- Monitor for the press release referenced in Item 8.01 (Exhibit 99.1) for additional strategic context.